Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 497

1.

Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens.

Lin KI, Tam CS, Keating MJ, Wierda WG, O'Brien S, Lerner S, Coombes KR, Schlette E, Ferrajoli A, Barron LL, Kipps TJ, Rassenti L, Faderl S, Kantarjian H, Abruzzo LV.

Blood. 2009 Apr 2;113(14):3168-71. doi: 10.1182/blood-2008-10-184853. Epub 2008 Dec 2.

2.

Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.

Byrd JC, Gribben JG, Peterson BL, Grever MR, Lozanski G, Lucas DM, Lampson B, Larson RA, Caligiuri MA, Heerema NA.

J Clin Oncol. 2006 Jan 20;24(3):437-43. Epub 2005 Dec 12.

3.

Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.

Robak T, Dmoszynska A, Solal-Céligny P, Warzocha K, Loscertales J, Catalano J, Afanasiev BV, Larratt L, Geisler CH, Montillo M, Zyuzgin I, Ganly PS, Dartigeas C, Rosta A, Maurer J, Mendila M, Saville MW, Valente N, Wenger MK, Moiseev SI.

J Clin Oncol. 2010 Apr 1;28(10):1756-65. doi: 10.1200/JCO.2009.26.4556. Epub 2010 Mar 1.

4.

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.

Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, Koller C, Wierda W, Detry MA, Lynn A, Kantarjian H.

J Clin Oncol. 2005 Jun 20;23(18):4079-88. Epub 2005 Mar 14.

5.

Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.

Foon KA, Boyiadzis M, Land SR, Marks S, Raptis A, Pietragallo L, Meisner D, Laman A, Sulecki M, Butchko A, Schaefer P, Lenzer D, Tarhini A.

J Clin Oncol. 2009 Feb 1;27(4):498-503. doi: 10.1200/JCO.2008.17.2619. Epub 2008 Dec 15.

6.

[Treatment of chronic lymphocytic leukemia with regimen of fludarabine, cyclophosphamide and rituximab].

Gu WJ, Xu W, Qian SX, Wu YJ, Hong M, Chen LJ, Wu HX, Lu H, Qiu HX, Li JY.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Aug;16(4):938-42. Chinese.

PMID:
18718095
7.

Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.

Bosch F, Ferrer A, Villamor N, González M, Briones J, González-Barca E, Abella E, Gardella S, Escoda L, Pérez-Ceballos E, Asensi A, Sayas MJ, Font L, Altés A, Muntañola A, Bertazzoni P, Rozman M, Aymerich M, Giné E, Montserrat E.

Clin Cancer Res. 2008 Jan 1;14(1):155-61. doi: 10.1158/1078-0432.CCR-07-1371.

8.

Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.

Byrd JC, Kipps TJ, Flinn IW, Castro J, Lin TS, Wierda W, Heerema N, Woodworth J, Hughes S, Tangri S, Harris S, Wynne D, Molina A, Leigh B, O'Brien S.

Blood. 2010 Jan 21;115(3):489-95. doi: 10.1182/blood-2009-08-237727. Epub 2009 Oct 20.

9.

Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses.

Lamanna N, Jurcic JG, Noy A, Maslak P, Gencarelli AN, Panageas KS, Heaney ML, Brentjens RJ, Golde DW, Scheinberg DA, Zelenetz AD, Weiss MA.

J Clin Oncol. 2009 Feb 1;27(4):491-7. doi: 10.1200/JCO.2008.16.4459. Epub 2008 Dec 15.

10.

5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen.

O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki AB, Koziner B, Chanan-Khan AA, Seymour JF, Gribben J, Itri LM, Rai KR.

J Clin Oncol. 2009 Nov 1;27(31):5208-12. doi: 10.1200/JCO.2009.22.5748. Epub 2009 Sep 8.

11.

Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.

Robak T, Lech-Maranda E, Robak P.

Expert Rev Anticancer Ther. 2010 Oct;10(10):1529-43. doi: 10.1586/era.10.132. Review.

PMID:
20942624
12.

[Prognostic significance of immunoglobulin variable region gene mutations in B-CLL patients treated with combination therapy fludarabine plus cyclophosphamide].

Nikitin EA, Stadnik EA, Lorie IuIu, Biderman BV, Tsyba NN, Salogub GN, Kolosheĭnova TI, Kolosova LIu, Risinskaia NA, Zaritskiĭ IuA, Kovaleva LG, Sudarikov AB.

Ter Arkh. 2007;79(7):66-70. Russian.

PMID:
17802794
13.

p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy.

Schlette EJ, Admirand J, Wierda W, Abruzzo L, Lin KI, O'Brien S, Lerner S, Keating MJ, Tam C.

Leuk Lymphoma. 2009 Oct;50(10):1597-605.

14.
15.

Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.

O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki A, Koziner B, Chanan-Khan AA, Seymour JF, Bociek RG, Pavletic S, Rai KR.

J Clin Oncol. 2007 Mar 20;25(9):1114-20. Epub 2007 Feb 12. Erratum in: J Clin Oncol. 2008 Feb 10;26(5):820.

16.

Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM, Hussein MA, Appelbaum FR, Larson RA, Moore DF Jr, Tallman MS.

J Clin Oncol. 2007 Mar 1;25(7):793-8. Epub 2007 Feb 5.

17.

Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia.

O'Brien SM, Kantarjian HM, Cortes J, Beran M, Koller CA, Giles FJ, Lerner S, Keating M.

J Clin Oncol. 2001 Mar 1;19(5):1414-20.

PMID:
11230486
18.

[Efficacy of chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia].

Fang C, Xu W, Xu M, Hong M, Zhu DX, Zhu HY, Wu YJ, Fan L, Qiao C, Zhuang Y, Miao KR, Liu P, Li JY.

Zhonghua Xue Ye Xue Za Zhi. 2011 Jan;32(1):3-7. Chinese.

PMID:
21429392
19.

Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).

Robak T, Jamroziak K, Gora-Tybor J, Stella-Holowiecka B, Konopka L, Ceglarek B, Warzocha K, Seferynska I, Piszcz J, Calbecka M, Kostyra A, Dwilewicz-Trojaczek J, Dmoszyñska A, Zawilska K, Hellmann A, Zdunczyk A, Potoczek S, Piotrowska M, Lewandowski K, Blonski JZ.

J Clin Oncol. 2010 Apr 10;28(11):1863-9. doi: 10.1200/JCO.2009.25.9630. Epub 2010 Mar 8.

20.

VH gene mutation status and cellular drug resistance in chronic lymphocytic leukaemia.

Aleskog A, Tobin G, Laurell A, Thunberg U, Lindhagen E, Roos G, Nilsson K, Nygren P, Sundström C, Höglund M, Larsson R, Rosenquist R.

Eur J Haematol. 2004 Dec;73(6):407-11.

PMID:
15522062
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk